Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04992962Phase 2Unknown

Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

Role: lead

NCT04679545Phase 2Unknown

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Role: lead

NCT04195269Phase 2Unknown

Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet

Role: lead

NCT04193631Phase 1Completed

Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain

Role: lead

NCT04088929Phase 2Completed

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

Role: lead

NCT04091789Phase 2Unknown

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

Role: lead

All 6 trials loaded